Xianjun Yu

68PUBLICATIONS
84CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyPredictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (68)

|Jul 06, 2026
Laparoscopic versus open pancreaticoduodenectomy for non-pancreatic periampullary adenocarcinomas: study protocol for a multicentre randomised controlled trial in China.

|Jun 02, 2026
The emerging role of disulfidptosis in metabolic synergistic death and cancer immunotherapy.

|May 28, 2026
Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer.

|Apr 13, 2026
Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer.

Chen Chen, Dingru Li, Yingna Liao

|Jan 06, 2026
Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition.

Di Wu, Chunbin Zhu, Haoqi Pan

|Dec 20, 2025
A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adenocarcinoma.

Ran Xue, Miaoyan Wei, Jiajia Yuan

Pageof 12

Frequent Collaborators

14 joint publications

Si Shi

9 joint publications

Xiaowu Xu

6 joint publications

Yi Qin

5 joint publications

Chen Liu